Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms By Ogkologos - August 6, 2025 539 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SAVANNAH study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR A Remarkable Group of Patients with Haematological Disorders with No or... December 15, 2021 ESMO Welcomes European Parliament Resolution Marking World Cancer Day February 11, 2026 For Early-Stage Cervical Cancer, Minimally Invasive Surgery Declining May 25, 2021 Long-Term Benefit of Nivolumab Plus Low-Dose Ipilimumab in Previously Treated Patients... June 30, 2022 Load more HOT NEWS HRQoL Data Support the Benefit of Adding Pembrolizumab to Chemotherapy in... GreaterGood Has Donated More Than 2 Million Masks to Frontline Workers... For Small Cell Lung Cancer, Immunotherapy Drug Finally Brings Improved Survival Brentuximab Approved for High-Risk Hodgkin Lymphoma in Children and Adolescents
